The Biology and Treatment of Myeloid Leukaemias
There has been an observed decrease in the global mortality from cancer, mostly atributable to improved, particularly early, detection and prevention. For many carcinomas and leukaemias in adults, once the disease has reached a certain stage there are no therapies that are able to erradicate the can...
Zapisane w:
| Główni autorzy: | , |
|---|---|
| Format: | Online |
| Język: | angielski |
| Wydane: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Hasła przedmiotowe: | |
| Dostęp online: | 26504 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|
| _version_ | 1869531224088772608 |
|---|---|
| author | Ewa Marcinkowska (Ed.) Geoffrey Brown (Ed.) |
| author_browse | Ewa Marcinkowska (Ed.) Geoffrey Brown (Ed.) |
| author_facet | Ewa Marcinkowska (Ed.) Geoffrey Brown (Ed.) |
| author_sort | Ewa Marcinkowska (Ed.) |
| collection | Directory of Open Access Books |
| description | There has been an observed decrease in the global mortality from cancer, mostly atributable to improved, particularly early, detection and prevention. For many carcinomas and leukaemias in adults, once the disease has reached a certain stage there are no therapies that are able to erradicate the cancer cells and cure patients. There has been progress in the treatment of acute myeloid leukaemia (AML) and remissions are achievable; however, the presence of chemoresistent blast cells leads to most patients relapsing, and relapse is difficult to treat and thus patients die due to their disease. Targeting these resistent cells and the leukaemia stem cells, which sustain the leukaemia, is crucial for an effective therapy for AML. Moreover, an increasing number of diverse mutations have been described in AML cells that disrupt the ability of these cells to undergo differentiation. The use of pro-differentiating agents to drive the blast cells to mature, and subsequently undergo apoptosis, provides another approach to therapy. Differentiation therapy, using all-trans retinoic acid (ATRA), an inducer of granulocyte differentiation, has been highly successful in the case of acute promyeloicytic leukaemia, a sub-type of AML, turning this disease into a curable malignancy. |
| format | Online |
| id | doab-20.500.12854ir-42238 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-422382024-03-31T22:43:42Z The Biology and Treatment of Myeloid Leukaemias Ewa Marcinkowska (Ed.) Geoffrey Brown (Ed.) RC254-282 mouse models myelopoiesis leukaemia stem cells gene aberrations new therapy strategies disease classification and diagnosis disease monitoring differentiation therapy cellular signaling and other molecular events acute myeloid leukaemias thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology There has been an observed decrease in the global mortality from cancer, mostly atributable to improved, particularly early, detection and prevention. For many carcinomas and leukaemias in adults, once the disease has reached a certain stage there are no therapies that are able to erradicate the cancer cells and cure patients. There has been progress in the treatment of acute myeloid leukaemia (AML) and remissions are achievable; however, the presence of chemoresistent blast cells leads to most patients relapsing, and relapse is difficult to treat and thus patients die due to their disease. Targeting these resistent cells and the leukaemia stem cells, which sustain the leukaemia, is crucial for an effective therapy for AML. Moreover, an increasing number of diverse mutations have been described in AML cells that disrupt the ability of these cells to undergo differentiation. The use of pro-differentiating agents to drive the blast cells to mature, and subsequently undergo apoptosis, provides another approach to therapy. Differentiation therapy, using all-trans retinoic acid (ATRA), an inducer of granulocyte differentiation, has been highly successful in the case of acute promyeloicytic leukaemia, a sub-type of AML, turning this disease into a curable malignancy. 2021-02-11T09:09:26Z 2021-02-11T09:09:26Z 2018-04-17 13:45:41 2018 book 26504 9783038427964 9783038427957 https://directory.doabooks.org/handle/20.500.12854/42238 eng image/png Attribution-NonCommercial-NoDerivatives 4.0 International http://www.mdpi.com/books/pdfview/book/586 http://www.mdpi.com/books/pdfview/book/586 MDPI - Multidisciplinary Digital Publishing Institute 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783038427964 9783038427957 VI, 190 open access |
| spellingShingle | RC254-282 mouse models myelopoiesis leukaemia stem cells gene aberrations new therapy strategies disease classification and diagnosis disease monitoring differentiation therapy cellular signaling and other molecular events acute myeloid leukaemias thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Ewa Marcinkowska (Ed.) Geoffrey Brown (Ed.) The Biology and Treatment of Myeloid Leukaemias |
| title | The Biology and Treatment of Myeloid Leukaemias |
| title_full | The Biology and Treatment of Myeloid Leukaemias |
| title_fullStr | The Biology and Treatment of Myeloid Leukaemias |
| title_full_unstemmed | The Biology and Treatment of Myeloid Leukaemias |
| title_short | The Biology and Treatment of Myeloid Leukaemias |
| title_sort | biology and treatment of myeloid leukaemias |
| topic | RC254-282 mouse models myelopoiesis leukaemia stem cells gene aberrations new therapy strategies disease classification and diagnosis disease monitoring differentiation therapy cellular signaling and other molecular events acute myeloid leukaemias thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| topic_facet | RC254-282 mouse models myelopoiesis leukaemia stem cells gene aberrations new therapy strategies disease classification and diagnosis disease monitoring differentiation therapy cellular signaling and other molecular events acute myeloid leukaemias thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| url | 26504 |
| work_keys_str_mv | AT ewamarcinkowskaed thebiologyandtreatmentofmyeloidleukaemias AT geoffreybrowned thebiologyandtreatmentofmyeloidleukaemias AT ewamarcinkowskaed biologyandtreatmentofmyeloidleukaemias AT geoffreybrowned biologyandtreatmentofmyeloidleukaemias |